Patients with prostatic cancer had higher kvels of TIMP-1 and collagenase (P = 0.0001) and lower levels of TIMP-2 (P = 0.003) than controk. Patients with metastatic cancer had sigficantly higher klvs of clanase than those without meastases (P = 0.02). Patients with rheumatoid arthritis had signifintly higher leviels of stromelysin than either controls (P = 0.002) or patients with cancer (P = 0.008). Serum tissue inhibitor of metalloprotenase 1 in combination with collagnase kvs was as sensitive as prostate-specific antigen as a marker of metastatic disea. Tese findings provide a basis for the investigation of the role of metalloproteinases and ther inhibitors in other malignances.
In a study of 750,000 patients with malignancy, approximately half of the patients who presented with apparently localised tumours subsequently died of metastases (Sugarbaker, 1981) . A major challenge for oncological practice is the identification of these patients with micrometastases at their initial presentation. The availability of more specific markers for micrometastases might then allow for the rational introduction of adjuvant chemotherapy or novel biological therapies and improve the prognosis (Waxman & Wasan, 1992) .
It is postulated that the progression of cancer may be the result of the activity of proteinases that facilitate invasion and metastasis by degrading the extraceliular tissue matrix. (Torti, 1983 One of these patients was subsequently found to have thyroid cancer and was excluded from the analysis. Sera from these patients were stored at -40-C, and used for this analysis. lagnase (code MAC64 and MAC66) and stromelysin (code MAC78) and rabbit antiserum was raised human stromelysin (Cooksley et al., 1990) . A similar procedure was used to raise a monoclonal to recombinant TEMP-2 (code MAC93). Antibodie MAC15 and MAC66 were biotinylated (Cooksley et al., 1990 Enzymes Recombinant human proteins were produced from cDNAs encoding human procollagnase, prostromelysin and TTMPs transfected into mammalian cells (Docherty et al., 1985; Murphy et al., 1987 (Docherty et al., 1985; Murphy et al., 1987) (pH 9.6 ). The plates were blocked for 1 h with 0.2% protease-free bovine serm albumin (BSA) (Sigma). Sample diluent contained 0.1% normal mouse serum (NMS) and 1.0% protease-free BSA in assay diluent. The revealing antibody was biotinylated MAC15 used at a concentration of 0.5 jgml-' in sample diluent. The conjugate was streptavidin-peroxidase at a concentration of 0.062 gg ml-' in conjugate diluent.
TIMP-2 reagents The solid phase reagent comprised microwell plates coated and blocked as above but with MAC93 coated at 1.0 ag ml-'. The sample dihuent contained 1.0% NMS, 1.0% protease-free BSA and 5.0% FCS in assay diuent. The revealing antibody was anti-TIMP-2 IgG at 1 pgg ml-' in sample diluent and the conjugate donkey antisheep IgG-peroxidase diluted to 1:20,000 in conjugate diluent.
Stromelysin reagents The solid phase reagent comprised microwell plates coated and blocked as above but with MAC78 coated at 5.0 gml-'. The sample diluent consisted of 0.1% NMS, 1.0% protease-free BSA and 5.0% normal horse serum in assay diluent. The revealing reagent was rabbit anti-stromelysin IgG at 5.0pjgml-' in sample diluent and the conjugated anti-rabbit IgG-peroxidase diluted to 1/ 20,000 in conjugate diluent.
Collagenase reagents The solid phase reagent comprised microwell plates coated and blocked as above but with MAC64 coated at 5.0 jg ml-' in phosphate-buffered saline. The sample diluent contained 0.1% NMS and 5.0% FCS in assay diluent. Biotinylated MAC66 at 0.25 jig ml-' in sample diluent was the revealing reagent. Conjugate, streptavidinperoxidase, was used at 0.25pgml-' in conjugate diluent.
ELISA method Antibodies at 5 g ml-' (MAC93 1 jug ml-') in 0.05 M carbonate buffer, pH 9.6, were used to coat (200 gpl for 18 h at 20-C) microwell plates (Nunc immunoplates) for the ELISAs. These were MAC19 (TIMP-1), MAC93 (TIMP-2), MAC78 (stromeysin) and MAC64 (collagenase). Wells were then blocked (400 gal, 1 h) with 0.2% (w/v) protease-free BSA in coating buffer.
For TIMP-, TIMP-2, colagnase and stromeysin ELISAs, 10 gl of sample (in duplicate) or standard (in triplicate) was added to a coated microwell followed by 200 Id of sample diluent [assay diluent containing 1% BSA (excepting collagenase), 0.01% mouse serum (1% for TIMP-2), 5% FCS (TIMP-2 and collagnase) and 5% horse serum (stromelysin)]. The wells were sealed and incubated for 1 h at 20-C with orbital shaking of the plate (300 r.p.m.), then washed with 4 x 400j1 of assay diluent.
Second and third incubation and wash stages were run under similar conditions employing 200 jlI aliquots of the following revealing antibody and conjugate solution: for TIMP-1 and collagnase, biotinylated antibodies, MAC1S (0.5 jig ml') and MAC66 (0.25 jg ml-') in sample diluent in combination with streptavidin-peroxidase conjugate (Celltech Ltd) at 0.062/0.25 jig ml-' in conjugate diluent (2% FCS in assay diluent); for TIMP-2 and stromelysin, polyclonal IgG, anti-TIMP-2 (1 jigml-') and anti-stromelysin (0.5jgml-') in sample diluent were used in combination with anti-species IgG-peroxidase conjugates (Jackson Immunoresearch) at 1 in 20,000 in conjugate diluent.
Colour development required a 0.5h incubation with a substrate mixture comprising 0.01% (w/v) 3,3',5,5'-tetramethylbenzidine (ICN), 1.0% (v/v) dimethylsulphoxide and 0.25% (w/v) P-cyclodextrin (Sigma) and 0.005% (v/v) hydrogen peroxide (BDH) in 0.1 M acetate buffer (pH 5.0) and was stopped by the addition of 50j1 of 2.5% sodium fluoride. Absorbance (630 nm) was measured using a Biotek EL31O plate reader (reference wavelength at 490 nm) and the data were reduced usng the Multicakc software package (Pharmada), whereby absorbance of unknowns was interpolated from calibration curves of absorbance plotted against molar concentration of the relevant metalloproteinase or TIMP standard. In contrast, mean stromelysin levels ( Figure Ib) were not significantly different between the cancer (1.05 nM) and noncancer control (1.02 nM) groups, whereas in the rheumatoid group mean stromelysin was raised over 3-fold (3.48 mM) as compared with cancer patients (P = 0.001). Figure Ic shows the molar ratio of collagenase to stromelysin in individual serum samples. Both cancer groups, particularly metastasispositive patients (P = 0.0001), had significantly increased ratios compared with the rheumatoid or hospital control groups.
Serwn TIMP concentrations Mean TIMP-1 concentration (Figure 2a ) in the cancer patients (12.9 nM) was highly significantly different from the hospital control group (9.8 nM), but was not significantly different from the rheumatoid group (11.7 rM). No difference was observed between metastasis-positive and -negative groups. In contrast, mean TIMP-2 levels ( Figure 2b) were lower in the prostatic cancer patients (3.1 nM) than in the hospital controls (3.5 nM) (P= 0.003) and rheumatoid patients (4.8 nM) (P = 0.0001). Figure Ic describes the ratio of TIMP-1 to TIMP-2. In prostate cancer groups serum TIMP-1 was in 4-fold molar excess over TIMP-2, falling to a 2.8-fold molar excess in the control group and a 1.5-fold molar excess in the rheumatoid group. The combined molarity of the two inhibitors was some 10-fold greater than the combined enzyme molarity.
Metalloproteinses and TIMP levels during prostate cancer treatment Figure 3 describes the temporal variation in means and standard deviations of metalloproteinase and TIMP levels in prostate cancer patients during the first 12 months of buserelin treatment compared with pretreatment levels. Patients were dividied into metastasis-negative (MO) and metastasis-positive (Ml) groups according to clinical diagnosis at the corresponding time point. There was a significant fall in collagnase levels in the MO (P= 0.015) and Ml (P = 0.0002) groups, and in stromelysin in the Ml subgroup (P = 0.03), at 6 months. TIMP-l mean levels showed a highly significant drop after 6 months' therapy (P = 0.0002). TIMP-2 levels increased in both groups after 6 months' treatment (P = 0.004). Collagnase and stromelysin levels remained depressed at 12 months of therapy, whereas TIMP-1 levels returned to baseline values. Undetectable I&
Predictive value analysis Non-parametric predictive value analysis was carried out on the baselne data in order to assess how each marker or combination of markers might predict disease outcome (Galen, 1984 compared with metastasis category at the 12 month time point. TIMP-1 was as efficient a marker as total or prostatic acid phosphatase for predicting the occurrence of metastases, with a diagnostic efficiency of 63%. Collagenase was a more efficient marker (71%) though not as sensitive as alkaline phosphatase (83%) or prostate-specific antigen (77%). However, raised serum TIMP-1 in combination with raised collagenase provided a similar degree of diagnostic efficiency (80%) as either alkaline phosphate or prostate-specific antigen (Table II) .
There was no correlation between Gleason grade and serum levels of the metalloproteinases or their inhibitors (data not shown).
Dicassion
In normal tissue matrix, turnover is low and metalloproteinase expression is not readily detectable, except during tissue remodelling and wound healing. The restoration of normal tissue structure requires a balanced interaction TIMP-2 levels (median and range) in patients with metastatic (M1) and non-metastatic (MO) prostatic cancer, prior to and after 6 and 12 months' treatment.
b between metalloproteinases and their inhibitors and matrix synthesis (Hembry & Ehrlich, 1986; Chowcat et al., 1988; Talhouk et al., 1992) . There is evidence of the disregulation of this balance in cancer, in which inappropriate expression of metalloproteinase activity or its inhibition is thought to facilitate tumour invasion and metastasis (Liotta et al., 1991) .
We have investigated whether it is possible to monitor this process by measuring levels of these enzymes and their inhibitors in the serum of patients with cancer. We have developed specific assays for serum collagenase and stromelysin which primarily detect and are calibrated against the proenzyme, but which also detect, at between 2-and 8-fold reduced potency, the active enzyme and enzyme-inhibitor complexes. Patient serum levels reported here thus broadly reflect total serum collagenase and total serum stromelysin levels respectively. We have also developed specific assays for serum TIMP-1 and TIMP-2 in which the predominant immunoreactive species is the free, noncomplexed inhibitor.
We have found that the serum levels of collagenase and TIMP-1 are elevated in patients with prostatic cancer and rheumatoid arthritis as compared with age-matched hospital controls. Collagenase levels were significantly higher in prostate cancer patients with metastases than in those without. In the prostate cancer patients, treatment with buserelin led to a fall in TIMP-1 and collagenase levels at 6 months. Collagenase levels ained depressed at 12 months, but TIMP-1 returned to pretherapy values. In contrast, the concentration of TIMP-2 was suppressed in the sera of patients with prostatic cancer and elevated in the sera of patients with rheumatoid arthritis -compared with the hospital control group sera. During buserelin therapy TIMP-2 levels inversely followed TIMP-1 levels, rising at 6 months and falling back to basal levels at 12 months.
It is at present uncertain whether the collagenase and TIMP-1 are tumour derived or result from stromal cell expression in response to tumour cell growth. In a previous immunohistological study of these proteins in colorectal cancer, antibody staining was shown to be localised to the stromal cells and not to neoplastic epithelial cells (Hewitt et al., 1991) . In the case of gelatinase A and stromelysin 3, recent results support the stromal expression hypothesis since, although these enzymes were immunolocalised to invasive tumours, the mRNA was shown by in situ hybridisation to be generated by surrounding stromal cells (Poulsom et al., 1992; Pyke et al., 1992; Wagner et al., 1992; Muller et al., 1993) . In contrast, gelatinase A is found in tumour cells (Stearns & Wang, 1993) .
Few comparative studies on the quantitation of metalloproteinases and their inhibitors in cancer have appeared in the literature. Collagenase and gelatinase A have been measured in tissue homogenates derived from patients with stomach carcinomas. Raised collagenase levels have been found at the advancing tumour edge as compared with adjacent normal tissue. In contrast, gelatinase A levels show a greater relative increase (Otani, 1990) . TIMP-1 has been examined in tissue extracts of colon cancer by competition ELISA and shown to be raised between 1.3-and 18.9-fold in 31 cases compared with paired samples of adjacent normal tissue (Lu et al., 1991) . Our data show that TIMP-1 serum concentration is some 10-fold greater than combined levels of collagnase and stromelysin for both cancer and control groups. Taken together with the very low dissociation constants (K, <lo-9 M) reported for the neutalisation of activated metalloproteinase by TIMP-l (Murphy et al., 1989) it is unlikely that either enzyme circulates in the active form.
In contrast, much higher levels of elatinase A have been reported, using ELISA, in normal human plasma (Zucker et al., 1989) and in st IV lung carcnoma sera (Garbisa et al., 1992) . Our findings of mean serum TIMP-1 lvels of 9.8 (range 6.3-15.6) nM in a non-cancer control group and 12.9 (range 6.9-19.7) nM in prostate cancer patients indiate that there may only be a small molar excess of non-complexed inhibitor over potentially active gelatinase A in the circulation.
There were significant difference in seru stromelysin levels in the different groups studied. Patients with rheumatoid arthritis were selected as controls in order to assess differences between the destructive processes in cancer and arthritides. It is diffiult to explain why serm stromelysin was signicantly elvated in the rheumatoid arthritis patients but not in the cancer patients. However; there are reports of elevated levels of stromelysin in the synovial fluid of patients with rheumatoid arthritis and traumatic knee injury (Walakcovits et al., 1991) . Taken together with the results presented here, this idicates that senim levels of stromelysin may be a useful marker of disease activity in inflammatory joint dissease. Our finding that the molar ratio of collagenase to stromelysin was more than 4-fold elevated in patients with prostate cancer as compared with patients with rheumatoid arthritis suggets that this parameter may be a useful discriminatory marker in those patients in whom one is trying to distinguish between arthritis or metastatic cancer on the basis of changes in plain radiographs or a bone scan.
Perhaps our most surprising fnding was that of raised levels of TIMP-1 in cancer patients' serum as compared with controls. It may be that this result represents a host response to aggressive tumour growth. In primary lung carcinomas TIMP-2 mRNA has been shown to be expressed by tumour cells and surrounding stroma, whereas TIMP-l is mainly expressed by the stroma (Urbanski et al., 1992) . Our results show that TIMP-2 serum levels are lower in prostate cancer patients than in hospital controls and show an inverse pattern to that of TIMP-1 during buserelin therapy. These are consistent with the findings of an increase in TIMP-1 mRNA and a decrease in TIMP-2 mRNA foliowing transforming growth factor (TGF) stimulation of a colorectal carcinoma explant which led the authors to conclude that TIMP-1 and TIMP-2 are independently regulated (Stetler-Stevenson et al., 1990) .
Whether the elevated serum levels of collagnase and TIMP-1 reported here are a direct result of their involvement in the mechanisms of malignancy in patients with metastatic diseas or an effect resulting from host tissue responses, our data suggest that the monitoring of these proteins in the serum may be prognostic for metastatic burden. It is of interest that a combination of high TIMP-l and collagnase levels detected at presentation in our study showed a diagnostic effciency of 80% in predicting the occurrence of metastasis -similar to that of alkaline phosphatase (83%) and prostate-specific antigen (77%).
A similar proposal has been made by Garbisa et al. (1992) , who found a strong correlation between serum gelatinase A levels and the presence of metastasis in lung cancer patients.
It is possible that the collagnase lvels are insufficent to overcome the inhibitory levels of TIMP-1, but that the greater levels of gelatinase A in the local environment of the tumour may allow the type IV cleaving properties of this enzyme to contribute to the metastatic phenotype. Recent results with cell lines individually transfected with either human collagenase or human gelatinase A genes suggest this to be the case (A. Docherty, in preparation). We are currently investigating the role of gelatinase A in the development of a metastatic phenotype through the use of synthetic gelatinase inhibitors, in models of metastatic disease, together with the development of specific quantitative assays for the gelatinase isoenzymes.
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